A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

• Main Authors: Yi J., Thongprasert S., Lee J., Doval D., Park S., Park J., Park Y., Kang W., Lim H.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84655161964&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/42930
• Institution: Chiang Mai University

Background: Biliary tract carcinoma (BTC) is rare in the West, but not uncommon in Asia and is a highly fatal malignancy. VEGF expression is related with poor outcome in patients with BTC. Therefore, we conducted a phase II study to evaluate the efficacy and safety of sunitinib as second-line treatm...